Affilogic is a private biotech company specialized in discovering and developing Nanofitins®-based therapeutics, through in house programs or collaborations with worldwide industry leaders in the pharmaceutical sector.
Recent news :
Mar 2025 – Affilogic’s new publication in Biomolecules : Jacquot & al. – A Multispecific Checkpoint Inhibitor Nanofitin with a Fast Tumor Accumulation Property and Anti-Tumor Activity in Immune Competent Mice
Mar 2025 – Affilogic is presenting at NextGen Biomed UK 2025 : Mathieu is presenting the latest data on our GiJob program, including in-vivo data of target engagement after oral administration of anti-inflammatory Nanofitins®.
Around the world
NextGen Biomed UK 2025
Affilogic will present at NextGen Biomed UK 2025 in London – UK
Mar 12-14, 2025
BIO EUROPE SPRING 2025
Affilogic will attend next BIO EUROPE Spring 2025 in Milan – Italy
Mar 17-19, 2025
World ADC London 2025
Affilogic will attend next World ADC in London – UK
Mar 3-6, 2025
Nanofitins
Each Nanofitin® is 20 times smaller than an antibody and demonstrates hyper stability. Their simple protein scaffold is particularly fitted for combination.
Read More
Our Programs
Affilogic develops therapeutic programs leveraging unique Nanofitins’ properties for brain delivery, inhalation of antivirals, oral GI treatments or small size drug conjugates.
Read More
NanoVector
Affilogic works with partners to deliver their therapeutic compounds to specific cells / organs with existing Nanofitins® or through custom generation of Nanofitins®.
Read More